A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Unresectable Hepatocellular Carcinoma

NCT07368023 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

300

Enrollment

OTHER_GOV

Sponsor class

Conditions

Hepatocellular Carcinoma
Hepatocellular Carcinoma Non-resectable

Interventions

COMBINATION_PRODUCT: Locoregional Therapy (LRT) + Systemic Drug Therapy

Sponsor

Ningbo Medical Center Lihuili Hospital